Novartis bought worldwide rights for a potential first-in-class experimental antibiotic from Paratek Pharmaceuticals to treat highly resistant bacteria. Soon after this deal, the large pharma entered into a US$200 M deal for using Heptares Therapeutics’ proprietary technology to fast track discovery against an unspecified GPCR target.